ES8704206A1 - Un procedimiento para la preparacion de un vector de dna recombinante - Google Patents

Un procedimiento para la preparacion de un vector de dna recombinante

Info

Publication number
ES8704206A1
ES8704206A1 ES551761A ES551761A ES8704206A1 ES 8704206 A1 ES8704206 A1 ES 8704206A1 ES 551761 A ES551761 A ES 551761A ES 551761 A ES551761 A ES 551761A ES 8704206 A1 ES8704206 A1 ES 8704206A1
Authority
ES
Spain
Prior art keywords
protein
activity
novel
produce
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES551761A
Other languages
English (en)
Other versions
ES551761A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24811674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8704206(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES551761A0 publication Critical patent/ES551761A0/es
Publication of ES8704206A1 publication Critical patent/ES8704206A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE VECTORES DE DNA RECOMBINANTE. CONSISTE EN EL CULTIVO DEL PLASMIDO EN UN MEDIO DE CULTIVO ADECUADO, A UNA TEMPERATURA PROXIMA A 37JC Y A CONTINUACION LIGAR UNA CADENA CODIFICANTE DEL PLASMIDO A UNA SECUENCIA DE DNA, EUCARIOTICA O PROCARIOTICA, ACTIVADORA DE LA TRANSCRIPCION Y DE LA TRADUCCION. TIENE APLICACIONES PARA LA PRODUCCION DE DERIVADOS DE LA PROTEINA C, EMPLEADOS EN EL TRATAMIENTO Y EN LA PREVENCION DE DIVERSOS TRASTORNOS VASCULARES.
ES551761A 1985-02-08 1986-02-07 Un procedimiento para la preparacion de un vector de dna recombinante Expired ES8704206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/699,967 US4775624A (en) 1985-02-08 1985-02-08 Vectors and compounds for expression of human protein C

Publications (2)

Publication Number Publication Date
ES551761A0 ES551761A0 (es) 1987-03-16
ES8704206A1 true ES8704206A1 (es) 1987-03-16

Family

ID=24811674

Family Applications (2)

Application Number Title Priority Date Filing Date
ES551761A Expired ES8704206A1 (es) 1985-02-08 1986-02-07 Un procedimiento para la preparacion de un vector de dna recombinante
ES557100A Expired ES8707764A1 (es) 1985-02-08 1986-09-30 Un metodo de produccion de un polipeptido con actividad de proteina c humana en una celula huesped

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES557100A Expired ES8707764A1 (es) 1985-02-08 1986-09-30 Un metodo de produccion de un polipeptido con actividad de proteina c humana en una celula huesped

Country Status (21)

Country Link
US (2) US4775624A (es)
EP (1) EP0191606B2 (es)
JP (6) JPH0698002B2 (es)
KR (1) KR860006546A (es)
CN (1) CN86100868A (es)
AT (1) ATE85079T1 (es)
AU (1) AU593538B2 (es)
CA (1) CA1341073C (es)
DE (2) DE3687584T4 (es)
DK (2) DK55486D0 (es)
ES (2) ES8704206A1 (es)
GR (1) GR860334B (es)
HU (1) HU211032B (es)
IE (1) IE59423B1 (es)
IL (1) IL77781A (es)
MY (1) MY103018A (es)
NZ (1) NZ215031A (es)
PH (1) PH25396A (es)
PT (1) PT81959B (es)
SG (1) SG50631A1 (es)
ZA (1) ZA86780B (es)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5981216A (en) * 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
ATE74164T1 (de) * 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
ATE93272T1 (de) * 1985-06-27 1993-09-15 Zymogenetics Inc Expression von protein c.
USRE38981E1 (en) * 1985-08-15 2006-02-14 Board Of Regents Of The University Of Washington DNA sequence coding for protein C
US5618715A (en) * 1985-12-20 1997-04-08 Oncogen Limited Partnership Oncostatin M and novel compositions having anti-neoplastic activity
GB8607502D0 (en) * 1986-03-26 1986-04-30 Antibioticos Sa Penicillium chrysogenum
US5550036A (en) * 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
IL98886A (en) * 1986-04-09 1992-12-01 Lilly Co Eli Method for producing a functional polypeptide in a eukaryotic cell
JPS63105675A (ja) * 1986-10-23 1988-05-10 Green Cross Corp:The ヒトウロキナ−ゼの製造方法
AU1187588A (en) * 1987-01-15 1988-08-10 Codon Genetic Engineering Laboratories Tandem gene eukaryotic expression vectors
WO1989012685A1 (en) * 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
DK260987D0 (da) * 1987-05-22 1987-05-22 Nordisk Gentofte Fremgangsmaade til fremstilling af et humant protein samt dna-sekvens til anvendelse ved udoevelse af fremgangsmaaden
JPS6445398A (en) * 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5196322A (en) * 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
JPH01285196A (ja) * 1988-05-11 1989-11-16 Chisso Corp 発光蛋白エクオリンの製造法
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
CA1332049C (en) * 1988-10-07 1994-09-20 Eli Lilly And Company Eukaryotic expression
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US6423313B1 (en) * 1988-12-30 2002-07-23 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
SE464135B (sv) * 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
EP0506821B1 (en) * 1989-12-29 1998-02-04 Zymogenetics, Inc. Hybrid protein c
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
EP0521873B1 (en) * 1990-01-29 1999-06-02 Zymogenetics, Inc. Anticoagulant proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
US6262336B1 (en) 1991-01-11 2001-07-17 American Red Cross Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
JPH06507307A (ja) * 1991-01-11 1994-08-25 アメリカン・レツド・クロス トランスジェニック動物の乳腺組織における活性ヒトプロテインｃの発現
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE69434332T2 (de) * 1993-11-12 2006-02-02 Gilead Sciences, Inc., Foster City Thrombin mutanten
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
AU710504B2 (en) 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
WO1995030429A1 (en) * 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
PT931148E (pt) 1996-10-16 2006-06-30 Zymogenetics Inc Homologos do factor de crescimento fibroblastico
ES2265159T3 (es) * 1996-11-08 2007-02-01 Oklahoma Medical Research Foundation Uso de una proteina c modificada.
US20060127387A1 (en) * 1997-04-22 2006-06-15 Zikria Bashir A Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions
US6159468A (en) * 1997-04-28 2000-12-12 Eli Lilly And Company Activated protein C formulations
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
KR20010013413A (ko) * 1997-06-05 2001-02-26 피터 지. 스트링거 혈전성 질환의 치료 방법
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
WO2000023101A1 (en) 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
CA2351067A1 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
CN1326356A (zh) 1998-11-20 2001-12-12 伊莱利利公司 治疗病毒性出血热的方法
AU1723200A (en) 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
AU1751801A (en) * 1999-11-19 2001-05-30 Eli Lilly And Company Protein c derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2001089558A2 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
AU2002210388B2 (en) * 2000-10-18 2006-11-23 Perseid Therapeutics Llc Protein C or activated protein C like molecules
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
WO2003007686A2 (en) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
EP1453529A4 (en) 2001-09-19 2007-09-26 Oklahoma Med Res Found TREATMENT OF SEPSIS WITH TAFI
US7308303B2 (en) * 2001-11-01 2007-12-11 Advanced Bionics Corporation Thrombolysis and chronic anticoagulation therapy
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20060094650A1 (en) * 2002-12-27 2006-05-04 Juridical Foundation The Chemo-Sero- Therapeutic Research Institute Agent for improving life expectancy in therapy of malignant tumor
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
JP4986618B2 (ja) * 2003-07-08 2012-07-25 ザ スクリプス リサーチ インスティチュート 通常の細胞保護活性を有するが抗凝固活性が低下した活性化プロテインｃ変異体
WO2005078074A2 (en) 2004-02-13 2005-08-25 Novozymes A/S Protease variants
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
KR20080071116A (ko) * 2005-06-24 2008-08-01 드럭리큐어 에이피에스 기도에 영향을 미치는 염증 질환에 있어서 활성화 단백질ｃ의 기도 투여법
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
WO2008048646A1 (en) * 2006-10-18 2008-04-24 Socratech L.L.C. Use of human protein c with altered glycosylation and sialic acid content as a medicament
WO2008073603A2 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
RU2469093C2 (ru) * 2008-12-19 2012-12-10 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
US4382028A (en) * 1982-07-19 1983-05-03 Monsanto Company Separation of plasma proteins from cell culture systems
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
ATE74164T1 (de) * 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin

Also Published As

Publication number Publication date
DE3687584T3 (de) 2001-05-03
JP2854282B2 (ja) 1999-02-03
KR860006546A (ko) 1986-09-13
EP0191606A2 (en) 1986-08-20
US4775624A (en) 1988-10-04
PT81959B (pt) 1988-07-01
JPH0759190B2 (ja) 1995-06-28
JP2854283B2 (ja) 1999-02-03
PT81959A (en) 1986-03-01
CA1341073C (en) 2000-08-08
DK55086A (da) 1986-08-09
DK55486D0 (da) 1986-02-05
NZ215031A (en) 1988-02-29
CN86100868A (zh) 1986-09-24
GR860334B (en) 1986-06-05
IE59423B1 (en) 1994-02-23
ES551761A0 (es) 1987-03-16
ES557100A0 (es) 1987-08-16
JPH10327876A (ja) 1998-12-15
US5151268A (en) 1992-09-29
JPH06189782A (ja) 1994-07-12
IE860328L (en) 1986-08-08
JPH09273A (ja) 1997-01-07
DK55086D0 (da) 1986-02-05
DE3687584T4 (de) 2001-07-26
EP0191606B1 (en) 1993-01-27
JPH0698002B2 (ja) 1994-12-07
EP0191606B2 (en) 2001-01-24
AU593538B2 (en) 1990-02-15
DE3687584T2 (de) 1993-05-27
ATE85079T1 (de) 1993-02-15
ZA86780B (en) 1987-09-30
PH25396A (en) 1991-06-03
JP2873153B2 (ja) 1999-03-24
JP2992002B2 (ja) 1999-12-20
ES8707764A1 (es) 1987-08-16
HU211032B (en) 1995-09-28
IL77781A (en) 1991-08-16
HUT40168A (en) 1986-11-28
JPS61205487A (ja) 1986-09-11
SG50631A1 (en) 1998-07-20
DE3687584D1 (de) 1993-03-11
JPH08317794A (ja) 1996-12-03
JPH06220092A (ja) 1994-08-09
AU5325686A (en) 1986-08-14
MY103018A (en) 1993-04-30
EP0191606A3 (en) 1987-01-21

Similar Documents

Publication Publication Date Title
ES8707764A1 (es) Un metodo de produccion de un polipeptido con actividad de proteina c humana en una celula huesped
ES2005073A6 (es) Procedimiento para preparar benzamidas y bencenoacetamidas
GR3033103T3 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
HK45193A (en) Ozone decontamination of blood and blood products
HU9204029D0 (en) Proteolytic enzym inhibitors
GR3004568T3 (es)
IL91276A0 (en) Pharmaceutical compositions containing alpha-amino boronic acid derivatives,for the prophylaxis and treatment of virus diseases
ZA866973B (en) Novel enolamides,pharmaceutical compositions and methods of use thereof for activity as modulators of the arachidonic acid cascade
EP0179808A4 (en) MEDICINAL COMPOSITION SUITABLE FOR TREATING OR PROPHYLAXIS OF HEART DISORDERS.
GR3015817T3 (en) Substituted alpha-amino acids having pharmaceutical activity.
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
HUT46046A (en) Process for producing compounds with nootropic effect and pharmaceutics comprising these as active ingredient
AU6560886A (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells
GR920100519A (el) Ενώσεις.
EP0278715A3 (en) Use of human gamma interferon for treatment of basal cell carcinoma
ATE78160T1 (de) Verwendung von ''naftidrofuryl'' zur behandlung von neuropathien.
MD105C2 (ro) Metodă de tratament al nevralgiei nervului trigemen

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20051224